Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of different intra-articular (i.a.) dosages of sprifermin in subjects with primary osteoarthritis of the knee (FORWARD)

Next Previous
Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of different intra-articular (i.a.) dosages of sprifermin in subjects with primary osteoarthritis of the knee (FORWARD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sprifermin (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Acronyms FORWARD
  • Sponsors EMD Serono; Merck KGaA

    • Most Recent Events

    • 15 Nov 2023 Results of a post-hoc analysis assessing effect of sprifermin on the symptomatic progression of knee OA (KOA) were presented at the ACR Convergence 2023.
    • 15 Nov 2023 Results of a post-hoc analysis assessing clinical and structural data from this study participants who underwent knee replacement in year 3-5 presented at the ACR Convergence 2023
    • 15 Nov 2023 Results of post hoc analysis investigating the impact of sprifermin treatment on dABs in KOA, presented at the ACR Convergence 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top